The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin.

Abstract

The therapeutic mechanism of action of methionine aminopeptidase 2 (MetAP2) inhibitors for obesity-diabetes has not yet been fully defined. Xenin, a K-cell derived peptide hormone, possesses an N-terminal Met amino acid residue. Thus, elevated xenin levels could represent a potential pharmacological mechanism of MetAP2 inhibitors, since long-acting xenin analogues have been shown to improve obesity-diabetes. The present study has assessed the ability of the MetAP2 inhibitor, TNP-470, to augment the antidiabetic utility of the incretin-enhancer drug, sitagliptin, in high fat fed (HFF) mice. TNP-470 (1 mg/kg) and sitagliptin (25 mg/kg) were administered once-daily alone, or in combination, to diabetic HFF mice (n = 10) for 18 days. Individual therapy with TNP-470 or sitagliptin resulted in numerous metabolic benefits including reduced blood glucose, increased circulating and pancreatic insulin and improved glucose tolerance, insulin sensitivity, pyruvate tolerance and overall pancreatic islet architecture. Further assessment of metabolic rate revealed that all treatments reduced respiratory exchange ratio and increased locomotor activity. All sitagliptin treated mice also exhibited increased energy expenditure. In addition, treatment with TNP-470 alone, or in combination with sitagliptin, reduced food intake and body weight, as well as elevating plasma and intestinal xenin. Importantly, combined sitagliptin and TNP-470 therapy was associated with further significant benefits beyond that observed by either treatment alone. This included more rapid restoration of normoglycaemia, superior glucose tolerance, increased circulating GIP concentrations and an enhanced pancreatic beta:alpha cell ratio. In conclusion, these data demonstrate that TNP-470 increases plasma and intestinal xenin levels, and augments the antidiabetic advantages of sitagliptin.

• Authors: Sarah L Craig, Victor A Gault, Peter R Flatt, Nigel Irwin
• Journal: Biochemical pharmacology (Biochem Pharmacol) Vol. 183 Pg. 114355 (01 2021) ISSN: 1873-2968 [Electronic] England
• PMID: 33279496 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 Elsevier Inc. All rights reserved.

Chemical References

• Blood Glucose
• Hypoglycemic Agents
• xenin 25
• Neurotensin
• Aminopeptidases
• methionine aminopeptidase 2
• Metalloendopeptidases
• Sitagliptin Phosphate
• O-(Chloroacetylcarbamoyl)fumagillol

Topics

• Aminopeptidases (antagonists & inhibitors, metabolism)
• Animals
• Blood Glucose (drug effects, metabolism)
• Diabetes Mellitus, Experimental (drug therapy, metabolism)
• Diet, High-Fat (adverse effects)
• Hypoglycemic Agents (administration & dosage)
• Male
• Metalloendopeptidases (antagonists & inhibitors, metabolism)
• Mice
• Mice, Inbred C57BL
• Neurotensin (biosynthesis)
• O-(Chloroacetylcarbamoyl)fumagillol (administration & dosage)
• Sitagliptin Phosphate (administration & dosage)
• Up-Regulation (drug effects, physiology)